BR112014023530A2 - diagnóstico farmacêutico - Google Patents
diagnóstico farmacêuticoInfo
- Publication number
- BR112014023530A2 BR112014023530A2 BR112014023530A BR112014023530A BR112014023530A2 BR 112014023530 A2 BR112014023530 A2 BR 112014023530A2 BR 112014023530 A BR112014023530 A BR 112014023530A BR 112014023530 A BR112014023530 A BR 112014023530A BR 112014023530 A2 BR112014023530 A2 BR 112014023530A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnosis
- pharmaceutical
- pharmaceutical diagnosis
- pi3k
- kits
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617284P | 2012-03-29 | 2012-03-29 | |
| US201361767848P | 2013-02-22 | 2013-02-22 | |
| PCT/EP2013/056600 WO2013144249A1 (en) | 2012-03-29 | 2013-03-27 | Pharmaceutical diagnostic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014023530A2 true BR112014023530A2 (pt) | 2017-07-18 |
Family
ID=48083130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014023530A BR112014023530A2 (pt) | 2012-03-29 | 2013-03-27 | diagnóstico farmacêutico |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9795596B2 (enExample) |
| EP (1) | EP2830621B1 (enExample) |
| JP (1) | JP6224067B2 (enExample) |
| KR (1) | KR20140138771A (enExample) |
| CN (1) | CN104271136A (enExample) |
| AR (1) | AR090544A1 (enExample) |
| AU (1) | AU2013241752B2 (enExample) |
| BR (1) | BR112014023530A2 (enExample) |
| CA (1) | CA2866127A1 (enExample) |
| CL (1) | CL2014002576A1 (enExample) |
| CO (1) | CO7091176A2 (enExample) |
| EA (1) | EA028984B1 (enExample) |
| EC (1) | ECSP14025016A (enExample) |
| ES (1) | ES2845560T3 (enExample) |
| GT (1) | GT201400206A (enExample) |
| HK (1) | HK1200723A1 (enExample) |
| IL (1) | IL234658B (enExample) |
| IN (1) | IN2014DN08970A (enExample) |
| MX (1) | MX2014011682A (enExample) |
| NZ (1) | NZ628596A (enExample) |
| PH (1) | PH12014502168A1 (enExample) |
| SG (2) | SG10201608001RA (enExample) |
| TW (1) | TW201345525A (enExample) |
| WO (1) | WO2013144249A1 (enExample) |
| ZA (1) | ZA201405938B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014229240B2 (en) * | 2013-03-15 | 2017-06-15 | Novartis Ag | Biomarkers of tumor pharmacodynamic response |
| EP3140427B1 (en) * | 2014-05-09 | 2020-10-14 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| KR102486126B1 (ko) * | 2014-10-03 | 2023-01-09 | 노파르티스 아게 | 알펠리십을 포함하는 제약 조성물 |
| US20180353515A1 (en) * | 2015-12-03 | 2018-12-13 | Novartis Ag | Treatment of cancer with a pi3k inhibitor in a patient presselected for having a pik3ca mutation in the ctdna |
| WO2019199860A1 (en) * | 2018-04-09 | 2019-10-17 | The Research Foundation For The State University Of New York | Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| EP0359789B1 (en) | 1988-01-21 | 1993-08-04 | Genentech, Inc. | Amplification and detection of nucleic acid sequences |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| EP0425563B1 (en) | 1988-07-20 | 1996-05-15 | David Segev | Process for amplifying and detecting nucleic acid sequences |
| US5169766A (en) | 1991-06-14 | 1992-12-08 | Life Technologies, Inc. | Amplification of nucleic acid molecules |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| GB2453173A (en) | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| EP2307414A4 (en) | 2008-07-07 | 2011-10-26 | Xcovery Holding Co Llc | SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| CN101445832B (zh) * | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| AR082418A1 (es) * | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
-
2013
- 2013-03-27 IN IN8970DEN2014 patent/IN2014DN08970A/en unknown
- 2013-03-27 AR ARP130101029 patent/AR090544A1/es unknown
- 2013-03-27 SG SG10201608001RA patent/SG10201608001RA/en unknown
- 2013-03-27 CN CN201380017393.0A patent/CN104271136A/zh active Pending
- 2013-03-27 EA EA201491787A patent/EA028984B1/ru not_active IP Right Cessation
- 2013-03-27 HK HK15101259.7A patent/HK1200723A1/xx unknown
- 2013-03-27 KR KR1020147026735A patent/KR20140138771A/ko not_active Ceased
- 2013-03-27 JP JP2015502341A patent/JP6224067B2/ja not_active Expired - Fee Related
- 2013-03-27 AU AU2013241752A patent/AU2013241752B2/en not_active Ceased
- 2013-03-27 NZ NZ628596A patent/NZ628596A/en not_active IP Right Cessation
- 2013-03-27 WO PCT/EP2013/056600 patent/WO2013144249A1/en not_active Ceased
- 2013-03-27 EP EP13715169.2A patent/EP2830621B1/en active Active
- 2013-03-27 CA CA 2866127 patent/CA2866127A1/en not_active Abandoned
- 2013-03-27 US US14/387,653 patent/US9795596B2/en not_active Expired - Fee Related
- 2013-03-27 BR BR112014023530A patent/BR112014023530A2/pt not_active IP Right Cessation
- 2013-03-27 ES ES13715169T patent/ES2845560T3/es active Active
- 2013-03-27 SG SG11201405169SA patent/SG11201405169SA/en unknown
- 2013-03-27 MX MX2014011682A patent/MX2014011682A/es unknown
- 2013-03-28 TW TW102111262A patent/TW201345525A/zh unknown
-
2014
- 2014-08-13 ZA ZA2014/05938A patent/ZA201405938B/en unknown
- 2014-09-15 IL IL234658A patent/IL234658B/en not_active IP Right Cessation
- 2014-09-26 PH PH12014502168A patent/PH12014502168A1/en unknown
- 2014-09-26 CL CL2014002576A patent/CL2014002576A1/es unknown
- 2014-09-29 CO CO14215143A patent/CO7091176A2/es unknown
- 2014-09-29 GT GT201400206A patent/GT201400206A/es unknown
- 2014-10-29 EC ECIEPI201425016A patent/ECSP14025016A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013241752B2 (en) | 2016-07-07 |
| SG10201608001RA (en) | 2016-11-29 |
| US20150111927A1 (en) | 2015-04-23 |
| ES2845560T3 (es) | 2021-07-27 |
| AR090544A1 (es) | 2014-11-19 |
| ZA201405938B (en) | 2015-11-25 |
| CN104271136A (zh) | 2015-01-07 |
| AU2013241752A1 (en) | 2014-09-25 |
| EP2830621B1 (en) | 2020-10-21 |
| EA028984B1 (ru) | 2018-01-31 |
| IL234658B (en) | 2018-02-28 |
| IN2014DN08970A (enExample) | 2015-05-22 |
| CL2014002576A1 (es) | 2015-01-23 |
| US9795596B2 (en) | 2017-10-24 |
| GT201400206A (es) | 2017-09-28 |
| HK1200723A1 (en) | 2015-08-14 |
| EA201491787A1 (ru) | 2015-01-30 |
| KR20140138771A (ko) | 2014-12-04 |
| PH12014502168A1 (en) | 2014-12-10 |
| JP6224067B2 (ja) | 2017-11-01 |
| CO7091176A2 (es) | 2014-10-21 |
| TW201345525A (zh) | 2013-11-16 |
| JP2015514080A (ja) | 2015-05-18 |
| WO2013144249A1 (en) | 2013-10-03 |
| NZ628596A (en) | 2015-10-30 |
| CA2866127A1 (en) | 2013-10-03 |
| SG11201405169SA (en) | 2014-10-30 |
| MX2014011682A (es) | 2015-01-22 |
| ECSP14025016A (es) | 2015-09-30 |
| EP2830621A1 (en) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| BR112015010059A2 (pt) | terapia adjuvante com inibidor da quinase da família tec | |
| GT201500249A (es) | Terapia de combinación | |
| BR112012017150A2 (pt) | formulação de anticorpo e regimes terapêuticos. | |
| BR112014023530A2 (pt) | diagnóstico farmacêutico | |
| BR112015010072A2 (pt) | imizado[1,2-a]piridinacarboxamidas substituídas com amino e sua utilização | |
| BR112014031310A2 (pt) | anticorpos anti-pcsk9, formulações, dosagem e métodos de uso | |
| BR112013033943A2 (pt) | sistema para uso com uma ou mais fontes de dados filiados de paciente, métodos para atualizar um conjunto de dados de orientação específico de paciente, atualizar uma pluralidade de bancos de dados de dispositivos de interface de paciente, operar um dispositivo de interface de paciente, administrar dados em um sistema, e, dispositivo de interface de paciente | |
| DOP2015000100A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| BR112015025711A2 (pt) | terapia de combinação com ibrutinibe | |
| BR112015012644A2 (pt) | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; | |
| BR112016030908A2 (pt) | moléculas com especificidade para cd45 e cd79 | |
| BR112015005227A2 (pt) | inibidores de glicosilceramida sintase | |
| BR112012012610A2 (pt) | terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma | |
| BR112016001114A2 (pt) | membros da família tnf direcionados modificados | |
| BR112013002250A2 (pt) | composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto. | |
| BR112013010574A2 (pt) | anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo | |
| BR112014002817A2 (pt) | Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 | |
| BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
| BR112014030406A8 (pt) | combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação | |
| BR112016008477A2 (pt) | Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| BR112014032916A2 (pt) | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2560 DE 28/01/2020. |